Výsledky vyhledávání - "Lesli A Kiedrowski"

Akademický článek

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors

Autor: David E Piccioni, Achal Singh Achrol, Lesli A Kiedrowski, Kimberly C Banks, Najee Boucher, Garni Barkhoudarian, Daniel F Kelly, Tiffany Juarez, Richard B Lanman, Victoria M Raymond, Minhdan Nguyen, Judy D Truong, Annie Heng, Jaya Gill, Marlon Saria, Sandeep C Pingle, Santosh Kesari

Publikováno v: CNS Oncology, Vol 8, Iss 2 (2019)

Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested cl

Externí odkaz: https://doaj.org/article/ef6262da7ada4d6092de61d74bc2de20

Zobrazit plný text záznamu

Akademický článek

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis

Autor: Ibiayi Dagogo-Jack, MD, Lesli A. Kiedrowski, MS, MPH, Rebecca S. Heist, MD, MPH, Jessica J. Lin, MD, Catherine B. Meador, MD, PhD, Elizabeth A. Krueger, NP, Andrew Do, BS, Jennifer Peterson, BS, Lecia V. Sequist, MD, MPH, Justin F. Gainor, MD, Jochen K. Lennerz, MD, PhD, Subba R. Digumarthy, MD

Publikováno v: JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100534- (2023)

Introduction: MET amplification is a potentially actionable resistance mechanism in ALK-rearranged (ALK+) lung cancer. Studies describing treatment outcomes of this molecular subgroup are lacking. Methods: We assembled a cohort of patients with ALK+

Externí odkaz: https://doaj.org/article/48f3d6a56b8d4f66bc9f438add97a0a8

Zobrazit plný text záznamu

Akademický článek

Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

BRCA1-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to BRCA2-mutated prostate cancer. The reason for this differential response is not clear. We hypothesized this differenti

Externí odkaz: https://doaj.org/article/4e03b0f2c01f46158e4c977641bd2a04

Zobrazit plný text záznamu

Akademický článek

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort

Autor: Stephen R. Fairclough, Lesli A. Kiedrowski, Jessica J. Lin, Ori Zelichov, Gabi Tarcic, Thomas E. Stinchcombe, Justin I. Odegaard, Richard B. Lanman, Alice T. Shaw, Rebecca J. Nagy

Publikováno v: Experimental Hematology & Oncology, Vol 8, Iss 1, Pp 1-6 (2019)

Abstract Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L792 mutations, a non-covalent m

Externí odkaz: https://doaj.org/article/a2642d01b2c14be0a9b216a7597b136a

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy

Autor: Saya L. Jacob, Lesli A. Kiedrowski, Young K. Chae

Publikováno v: Heliyon, Vol 6, Iss 5, Pp e03841- (2020)

Background: Reversion mutations of somatic BRCA mutations are an important source of resistance within ovarian cancer. Furthermore, these reversion mutations are known to change over the course of treatment. Better understanding of the mechanisms lea

Externí odkaz: https://doaj.org/article/b27777be51ee420083590ccb8e9feb47

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání